Answers are grounded in this paper and cite their sources.
Nonsegmental vitiligo is a chronic autoimmune disorder in which interferon-gamma-driven, CD8+ T-cell-mediated destruction of melanocytes is sustained through Janus kinase (JAK) 1/2 signaling. Ruxolitinib 1.5% cream, a topical JAK1/2 inhibitor, was the first therapy approved specifically for vitiligo, based on phase 3 trials showing clinically meaningful facial and total-body repigmentation. Narrowband ultraviolet B (NB-UVB) phototherapy, the long-standing first-line option for widespread disease, acts through complementary mechanisms that include stimulation of melanocyte proliferation and migration from follicular reservoirs. This narrative review summarizes the evidence supporting the combination of topical ruxolitinib with NB-UVB, with emphasis on patients who respond poorly to monotherapy, regional differences in response, and safety. In an exploratory phase 2 study, patients with less than 25% improvement in the total Vitiligo Area Scoring Index (T-VASI) after 12 weeks of ruxolitinib cream added home NB-UVB, and those evaluable at week 48 achieved a mean T-VASI reduction of approximately 50%, with no new safety signals. In a long-term extension of an earlier phase 2 trial, the addition of NB-UVB further improved facial and total-body repigmentation in most patients. Meta-analytic data, derived largely from oral JAK inhibitors, also suggest additive benefit of phototherapy. Response is strongly determined by anatomical site: the face responds best, whereas acral sites remain resistant. Adverse events of the combination have been predominantly mild and local. Current evidence, although limited by small, mostly nonrandomized studies, supports adding NB-UVB to topical ruxolitinib in patients with inadequate early response, while randomized trials are needed.
No takes yet. Share an insight, caveat, or question.
Sylvana Cruz Navarro (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: